LEUPROLIDE ACETATE | N205054 | INVAGEN PHARMACEUTICALS INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 2 | Active | Jonsson Comprehensive Cancer Center | 28 | 2021-03-17 → 2028-01-01 | |
| Phase 2/3 | Active | Sir Mortimer B. Davis - Jewish General Hospital | 102 | 2016-10 → 2041-08 | |
| Phase 3 | Active | Alliance for Clinical Trials in Oncology | 788 | 2007-05-08 → 2030-10 | |
| Phase 1/2 | Active | University of Michigan Rogel Cancer Center | 102 | 2020-11-06 → 2029-05 | |
| Phase 2 | Active | Fondazione Sandro Pitigliani | 116 | 2018-12-27 → 2025-11-27 | |
| Phase 3 | Active | Pfizer | 1,068 | 2014-12-17 → 2026-09-19 | |
| Phase 2 | Active | Mark Stein | 26 | 2019-05-16 → 2028-04 | |
| Phase 2 | Active | M.D. Anderson Cancer Center | 310 | 2013-02-05 → 2027-02-01 | |
| Phase 2 | Active | City of Hope Medical Center | 29 | 2006-07-18 → 2027-02-15 | |
| Phase 1 | Active | Thomas Jefferson University | 25 | 2014-04-02 → 2040-01-01 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
Lowest Price
$231.63
Highest Price
$238.60
FSS NDCs
2
Big4 NDCs
0
| Description | Price | Type | Vendor | Contract End |
|---|---|---|---|---|
| 69097-0909-50LEUPROLIDE ACETATE 22.5MG (3 MONTH) INJ,SUSP, | $231.63 | FSS | Cipla USA, Inc. | 08/14/2026 |
| 83831-0134-01LUTRATE DEPOT 22.5MG | $238.60 | FSS | Avyxa Pharma, LLC | 05/14/2030 |
Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.
15 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Nov 15, 2024 | SUPPL -7 | View Letter (PDF) |
| Aug 9, 2024 | SUPPL -6 | View Letter (PDF) |
| Dec 1, 2023 | SUPPL -5 | View Letter (PDF) |
| Mar 1, 2023 | SUPPL -4 | View Letter (PDF) |
| Sep 18, 2018 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.